July 2016
GenMark Diagnostics, Inc.
Canaccord Genuity acts as Sole Placement Agent for US$30.0 million at-the-market offering of common stock by GenMark Diagnostics, Inc.
Canaccord Genuity is pleased to announce that it has completed an at-the-market (“ATM”) offering of common stock for GenMark Diagnostics, Inc. (NasdaqGM:GNMK). On June 14, 2016, Canaccord Genuity entered into an Equity Distribution Agreement with GenMark Diagnostics, Inc., under which it could offer and sell, from time to time, up to $30.0 million of common stock. On November 3, 2016, GenMark Diagnostics, Inc. announced that they had raised $28.9 million of net cash from the issue of 3.3 million shares of common stock under their ATM facility. Canaccord Genuity acted as Sole Placement Agent for the offering.
GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. The eSensor detection technology is also incorporated into GenMark's sample-to-answer system, ePlex®.
